49 results on '"Svobodova B"'
Search Results
2. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
- Author
-
Chocova, Z., Hruskova, Z., Mareckova, H., Svobodova, B., Duskova, D., Bednarova, V., Jancova, E., Rysava, R., and Tesar, V.
- Published
- 2015
- Full Text
- View/download PDF
3. The importance of experimental milieu in regulation of macrophage activation: 1.21
- Author
-
Pekarova, M., Lojek, A., Martiskova, H., Klinke, A., Rudolph, T., Svobodova, B., Maceckova, M., Kuchta, R., Kadlec, J., Kuchtova, Z., and Kubala, L.
- Published
- 2013
4. SaO055SEX DIFFERENCES AND CLINICAL OUTCOMES IN THE MEMBRANOUS NEPHROPATHY REGISTRY
- Author
-
van de Luijtgaarden, M, primary, van de Logt, A, additional, Winterbottom, J, additional, Brenchley, P, additional, Svobodova, B, additional, Tesar, V, additional, Dahan, K, additional, Debiec, H, additional, Ronco, P, additional, van den Brand, J A, additional, Vink, C, additional, and Wetzels, J, additional
- Published
- 2018
- Full Text
- View/download PDF
5. Design of spectrophotometer for neonatal phototherapy
- Author
-
Svobodova, B., primary, Penhaker, M., additional, Kasik, V., additional, Augustynek, M., additional, and Kubicek, J., additional
- Published
- 2017
- Full Text
- View/download PDF
6. A calcium-accumulating region, CAR, in the channel Orai1 enhances Ca2+ permeation and SOCE-induced gene transcription
- Author
-
Frischauf, I., primary, Zayats, V., additional, Deix, M., additional, Hochreiter, A., additional, Jardin, I., additional, Muik, M., additional, Lackner, B., additional, Svobodova, B., additional, Pammer, T., additional, Litvi ukova, M., additional, Sridhar, A. A., additional, Derler, I., additional, Bogeski, I., additional, Romanin, C., additional, Ettrich, R. H., additional, and Schindl, R., additional
- Published
- 2015
- Full Text
- View/download PDF
7. Increased Levels of Soluble ST2 in Patients with Active Newly Diagnosed ANCA-Associated Vasculitis
- Author
-
Hladinova, Z., primary, Hruskova, Z., additional, Svobodova, B., additional, Malickova, K., additional, Lanska, V., additional, Konopásek, P., additional, Jancova, E., additional, Rysava, R., additional, Edelstein, C. L., additional, and Tesar, V., additional
- Published
- 2015
- Full Text
- View/download PDF
8. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters
- Author
-
Chocova, Z., primary, Hruskova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Duskova, D., additional, Bednarova, V., additional, Jancova, E., additional, Rysava, R., additional, and Tesar, V., additional
- Published
- 2014
- Full Text
- View/download PDF
9. Renal vasculitis
- Author
-
Manenti, L., primary, Signorini, L., additional, Gnappi, E., additional, Pilato, F. P., additional, Vaglio, A., additional, Allegri, L., additional, Buzio, C., additional, Bertram, A., additional, Lovric, S., additional, Park, J.-K., additional, Becker, J. U., additional, Haubitz, M., additional, Kirsch, T., additional, Jancova, E., additional, Hruskova, Z., additional, Lanska, V., additional, Sedova, L., additional, Olsanska, R., additional, Jilek, D., additional, Nemejc, P., additional, Tesar, V., additional, Maritati, F., additional, Urban, M., additional, Oliva, E., additional, Alberici, F., additional, Smith, R., additional, Jones, R., additional, Jayne, D., additional, Chocova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Bednarova, V., additional, and Rysava, R., additional
- Published
- 2013
- Full Text
- View/download PDF
10. Serial chest high-resolution CT (HRCT) scans in patients with ANCA-associated vasculitis
- Author
-
Konopasek, P., primary, Altmanova, D., additional, Hruskova, Z., additional, Jancova, E., additional, Svobodova, B., additional, and Tesar, V., additional
- Published
- 2013
- Full Text
- View/download PDF
11. Rituximab use in patients with ANCA-associated vasculitis: Clinical efficacy and impact on immunological parameters
- Author
-
Chocova, Z., primary, Hruskova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Bednarova, V., additional, Jancova, E., additional, Rysava, R., additional, and Tesar, V., additional
- Published
- 2013
- Full Text
- View/download PDF
12. Long-term outcome of severe alveolar hemorrhage in ANCA-associated vasculitis: A retrospective cohort study
- Author
-
Hruskova, Z., primary, Casian, A., additional, Konopasek, P., additional, Svobodova, B., additional, Frausova, D., additional, Lanska, V., additional, Tesar, V., additional, and Jayne, D., additional
- Published
- 2013
- Full Text
- View/download PDF
13. Long-term outcome of severe alveolar haemorrhage in ANCA-associated vasculitis: a retrospective cohort study
- Author
-
Hruskova, Z, primary, Casian, AL, additional, Konopasek, P, additional, Svobodova, B, additional, Frausova, D, additional, Lanska, V, additional, Tesar, V, additional, and Jayne, DRW, additional
- Published
- 2013
- Full Text
- View/download PDF
14. Primary and secondary glomerulonephritis I
- Author
-
Miyazaki, N., primary, Matsumoto, J., additional, Alberici, F., additional, Palmisano, A., additional, Maritati, F., additional, Oliva, E., additional, Buzio, C., additional, Vaglio, A., additional, Mjoen, G., additional, Norby, G. E., additional, Vikse, B. E., additional, Svarstad, E., additional, Rune, B., additional, Knut, A., additional, Szymczak, M., additional, Kuzniar, J., additional, Kopec, W., additional, Marchewka, Z., additional, Klinger, M., additional, Arrizabalaga, P., additional, Silvarino, R., additional, Sant, F., additional, Espinosa, G., additional, Sole, M., additional, Cervera, R., additional, Gude, D., additional, Chennamsetty, S., additional, Demin, A., additional, Kozlov, V., additional, Lisukov, I., additional, Kotova, O., additional, Sizikov, A., additional, Sergeevicheva, V., additional, Demina, L., additional, Borjesson, O., additional, Wendt, M., additional, Avik, A., additional, Qureshi, A. R., additional, Bratt, J., additional, Miller, E. J., additional, Gunnarsson, I., additional, Bruchfeld, A., additional, Sugiyama, K., additional, Hasegawa, M., additional, Yamamoto, K., additional, Hayashi, H., additional, Koide, S., additional, Murakami, K., additional, Tomita, M., additional, Yoshida, S., additional, Yuzawa, Y., additional, Yew, S., additional, Jayne, D., additional, Westman, K., additional, Hoglund, P., additional, Flossman, O., additional, Mahr, A., additional, Luqmani, R., additional, Robson, J., additional, Thervet, E., additional, Levi, C., additional, Guiard, E., additional, Roland, M., additional, Nochy, D., additional, Daniliuc, C., additional, Guillevin, L., additional, Mouthon, L., additional, Jacquot, C., additional, Karras, A., additional, Kimura, Y., additional, Morita, H., additional, Debiec, H., additional, Yamada, H., additional, Miura, N., additional, Banno, S., additional, Ronco, P., additional, Imai, H., additional, Shin, D. H., additional, Famee, D., additional, Koo, H. M., additional, Han, S. H., additional, Choi, K. H., additional, Yoo, T.-H., additional, Kang, S.-W., additional, Fofi, C., additional, Scabbia, L., additional, Festuccia, F., additional, Stoppacciaro, A., additional, Mene', P., additional, Shimizu, A., additional, Fukui, M., additional, MII, A., additional, Kaneko, T., additional, Masuda, Y., additional, Iino, Y., additional, Katayama, Y., additional, Fukuda, Y., additional, Kuroki, A., additional, Matsumoto, K., additional, Akizawa, T., additional, Jurubita, R., additional, Ismail, G., additional, Bobeica, R., additional, Rusu, E., additional, Zilisteanu, D., additional, Andronesi, A., additional, Motoi, O., additional, Ditoiu, V., additional, Copaci, I., additional, Voiculescu, M., additional, Irazabal, M. V., additional, Eirin, A., additional, Lieske, J. C., additional, Beck, L. H., additional, Dillon, J. J., additional, Nachman, P. H., additional, Sethi, S., additional, Erickson, S. B., additional, Cattran, D. C., additional, Fervenza, F. C., additional, Svobodova, B., additional, Hruskova, Z., additional, Janatkova, I., additional, Jancova, E., additional, Tesar, V., additional, Seo, M. S., additional, Kwon, S. H., additional, Lee, E. B., additional, You, J. Y., additional, Hyun, Y. K., additional, Woo, S. A., additional, Park, M. Y., additional, Choi, S. J., additional, Jeon, J. S., additional, Noh, H., additional, Kim, J. G., additional, Han, D. C., additional, Hwang, S. D., additional, Choi, T. Y., additional, Jin, S. Y., additional, Loiacono, E., additional, Defedele, D., additional, Puccinelli, M. P., additional, Camilla, R., additional, Gallo, R., additional, Peruzzi, L., additional, Rollino, C., additional, Beltrame, G., additional, Ferro, M., additional, Vergano, L., additional, Campolo, F., additional, Amore, A., additional, Coppo, R., additional, Knoop, T., additional, Bostad, L., additional, Leivestad, T., additional, Bjorneklett, R., additional, Teranishi, J., additional, Yamamoto, R., additional, Nagasawa, Y., additional, Shoji, T., additional, Iwatani, H., additional, Okada, N., additional, Moriyama, T., additional, Yamauchi, A., additional, Tsubakihara, Y., additional, Imai, E., additional, Rakugi, H., additional, Isaka, Y., additional, Doh, F. M., additional, Kim, S. J., additional, Han, D. S., additional, Suzuki, Y., additional, Matsuzaki, K., additional, Suzuki, H., additional, Okazaki, K., additional, Yanagawa, H., additional, Maiguma, M., additional, Muto, M., additional, Sato, T., additional, Horikoshi, S., additional, Novak, J., additional, Hotta, O., additional, Tomino, Y., additional, Gutierrez*, E., additional, Zamora, I., additional, Ballarin, J., additional, Arce, Y., additional, Jimenez, S., additional, Quereda, C., additional, Olea, T., additional, Martinez-Ara, J., additional, Segarra, A., additional, Bernis, C., additional, Garcia, A., additional, Goicoechea, M., additional, Garcia de Vinuesa, S., additional, Rojas, J., additional, Praga, M., additional, Ristovska, V., additional, Petrushevska, G., additional, Grcevska, L., additional, Satake, K., additional, Shimizu, Y., additional, Mugitani, N., additional, Honda, S., additional, Shibuya, K., additional, Shibuya, A., additional, Papale, M., additional, Rocchetti, M. T., additional, DI Paolo, S., additional, Suriano, I. V., additional, D'apollo, A., additional, Vocino, G., additional, Montemurno, E., additional, Varraso, L., additional, Grandaliano, G., additional, Gesualdo, L., additional, Huerta, A., additional, Bomback, A. S., additional, Canetta, P. A., additional, Radhakrishnan, J., additional, Herlitz, L., additional, Stokes, B., additional, D'agati, V., additional, Markowitz, G., additional, Appel, G. B., additional, Mouna, H., additional, Nasr, B. D., additional, Mrabet, I., additional, Ahmed, L., additional, Sabra, A., additional, Mohamed Ammeur, F., additional, Mezri, E., additional, Habib, S., additional, Innocenti, M., additional, Pasquariello, A., additional, Pasquariello, G., additional, Mattei, P., additional, Bottai, A., additional, Fumagalli, G., additional, Bozzoli, L., additional, Samoni, S., additional, Cupisti, A., additional, Caldin, B., additional, Hung, J., additional, Repizo, L., additional, Malheiros, D. M., additional, Barros, R., additional, Woronik, V., additional, Giammarresi, C., additional, Bono, L., additional, Ferrantelli, A., additional, Tortorici, C., additional, Licavoli, G., additional, Rotolo, U., additional, Huang, X., additional, Wang, Q., additional, Shi, M., additional, Chen, W., additional, Liu, Z., additional, Scarpioni, R., additional, Cantarini, L., additional, Lazzaro, A., additional, Ricardi, M., additional, Albertazzi, V., additional, Melfa, L., additional, Concesi, C., additional, Vallisa, D., additional, Cavanna, L., additional, Gungor, G., additional, Ataseven, H., additional, Demir, A., additional, Solak, Y., additional, Biyik, M., additional, Ozturk, B., additional, Polat, I., additional, Kiyici, A., additional, Ozer Cakir, O., additional, Polat, H., additional, Castillo, I., additional, Carreno, V., additional, Aguilar, A., additional, Madero, R., additional, Hernandez, E., additional, Bartolome, J., additional, Gea, F., additional, Selgas, R., additional, El Aggan, H. A. M., additional, El Banawy, H. S., additional, Wagdy, E., additional, Tchebotareva, N., additional, LI, O., additional, Bobkova, I., additional, Kozlovskaya, L., additional, Varshavskiy, V., additional, Golicina, E., additional, Chen, Y., additional, Gong, Z., additional, Chen, X., additional, Tang, L., additional, Zhou, J., additional, Cao, X., additional, Wei, R., additional, Koo, E. H., additional, Park, J. H., additional, Kim, H. K., additional, Kim, M. S., additional, Jang, H. R., additional, Lee, J. E., additional, Huh, W., additional, Kim, D. J., additional, Oh, H. Y., additional, Kim, Y.-G., additional, Eskova, O., additional, Shvetsov, M., additional, Golytsina, E., additional, Popova, O., additional, Quaglia, M., additional, Monti, S., additional, Fenoglio, R., additional, Menegotto, A., additional, Airoldi, A., additional, Izzo, C., additional, Rizzo, M. A., additional, Dianzani, U., additional, Stratta, P., additional, and Gianfreda, D., additional
- Published
- 2012
- Full Text
- View/download PDF
15. Primary and secondary glomerulonephritis II
- Author
-
Valdivia Vega, R. P., primary, Perez Carlos, J., additional, LI, X., additional, Xu, X., additional, Zhang, W., additional, Ren, H., additional, Chen, N., additional, Yorioka, N., additional, Doi, T., additional, Hirashio, S., additional, Arita, M., additional, Hirabayashi, A., additional, Tilkiyan, E., additional, Chonova, E., additional, Ronchev, Y., additional, Kumchev, E., additional, Giamalis, P., additional, Spartalis, M., additional, Stangou, M., additional, Tsouchnikas, I., additional, Moysiades, D., additional, Dimopoulou, D., additional, Garyfalos, A., additional, Efstratiadis, G., additional, Memmos, D., additional, Schonermarck, U., additional, Eichhorn, P., additional, Sitter, T., additional, Wendler, T., additional, Vielhauer, V., additional, Lederer, S., additional, Fechner, K., additional, Fischereder, M., additional, Bantis, C., additional, Heering, P., additional, Kouri, N.-M., additional, Schwandt, C., additional, Kuhr, N., additional, Ivens, K., additional, Rump, L.-C., additional, Matta, V., additional, Melis, P., additional, Conti, M., additional, Cao, R., additional, Binda, V., additional, Altieri, P., additional, Asunis, A. M., additional, Catani, W., additional, Floris, M., additional, Angioi, A., additional, Congia, M., additional, Cucca, F., additional, Minerba, L., additional, Peri, M., additional, Pani, A., additional, Beck, L. H., additional, Fervenza, F. C., additional, Bomback, A. S., additional, Ayalon, R., additional, Irazabal, M. V., additional, Eirin, A., additional, Cattran, D. C., additional, Appel, G. B., additional, Salant, D. J., additional, Santoro, D., additional, Postorino, A., additional, Costantino, G., additional, Bellinghieri, G., additional, Savica, V., additional, Weiner, M., additional, Goh, S. M., additional, Mohammad, A., additional, Eriksson, P., additional, Westman, K., additional, Selga, D., additional, Salama, A., additional, Segelmark, M., additional, Chocova, Z., additional, Hruskova, Z., additional, Mareckova, H., additional, Svobodova, B., additional, Jancova, E., additional, Bednarova, V., additional, Rysava, R., additional, Tesar, V., additional, Hanzal, V., additional, Zamboch, K., additional, Grussmannova, M., additional, Svojanovsky, J., additional, Klaboch, J., additional, Kubisova, M., additional, Sevcik, J., additional, Olsanska, R., additional, Sobotkova, M., additional, Becvar, R., additional, Nemec, P., additional, Kodeda, M., additional, Jilek, D., additional, Hussain, M., additional, Dhaygude, A., additional, Cartery, C., additional, Huart, A., additional, Plaisier, E., additional, Bongard, V., additional, Montastruc, F., additional, Ronco, P., additional, Pourrat, J., additional, Chauveau, D., additional, Prasad, N., additional, Gurjar, D., additional, Bhadauria, D., additional, Sharma, R. K., additional, Gupta, A., additional, Kaul, A., additional, Jain, M., additional, Venning, M., additional, Brown, N., additional, Bruce, I., additional, Noor, S., additional, Bekker, P., additional, Potarca, A., additional, Dairaghi, D., additional, Miao, S., additional, Powers, J. P., additional, Jaen, J. C., additional, Schall, T. J., additional, Kalavrizioti, D., additional, Gerolymos, M., additional, Komninakis, D., additional, Rodi, M., additional, Mouzaki, A., additional, Kalliakmani, P., additional, Goumenos, D., additional, Choi, B. S., additional, Park, C. W., additional, Kim, Y.-S., additional, Yang, C. W., additional, Sun, I. O., additional, Qin, W., additional, Xie, L., additional, Tan, C., additional, Mian, W., additional, Fu, P., additional, Kaminskyy, V., additional, Hao, X., additional, Wang, W., additional, Cengiz, C., additional, Nur, C., additional, Nurdan, Y., additional, Selman, G., additional, Pinar, T., additional, Mehmet, T., additional, Lale, S., additional, Caliskan, S., additional, Shinzawa, M., additional, Yamamoto, R., additional, Nagasawa, Y., additional, Oseto, S., additional, Mori, D., additional, Niihata, K., additional, Fukunaga, M., additional, Yamauchi, A., additional, Tsubakihara, Y., additional, Rakugi, H., additional, Isaka, Y., additional, Chen, J.-S., additional, Lin, Y.-F., additional, Lin, W.-Y., additional, Shu, K.-H., additional, Chen, H.-H., additional, Wu, C.-J., additional, Yang, C.-S., additional, Tseng, T.-L., additional, Zaza, G., additional, Bernich, P., additional, Lupo, A., additional, Panizo, N., additional, Rivera, F., additional, Lopez Gomez, J. M., additional, Regn, S. R. o. G., additional, Ceresini, G., additional, Vaglio, A., additional, Urban, M. L., additional, Corradi, D., additional, Usberti, E., additional, Palmisano, A., additional, Buzio, C., additional, Zineb, H., additional, Ramdani, B., additional, Marques, L. P. J., additional, Rioja, L. D. S., additional, Rocco, R., additional, Nery, A. C. F., additional, Novaes, B. C., additional, Bridoux, F., additional, Sicard, A., additional, Labatut, D., additional, Touchard, G., additional, Sarkozy, C., additional, Vanhille, P., additional, Callard, P., additional, Essig, M., additional, Provot, F., additional, Nony, A., additional, Karras, A., additional, Agustin, C. P., additional, M Belen, H. R., additional, Carmen, C. P., additional, Eliana, O., additional, Elisa, P., additional, Luis, P., additional, Alberto, M.-C., additional, Javier, N., additional, Isabel, F., additional, Atzeni, A., additional, Fois, A., additional, Piras, D., additional, Maxia, S., additional, Sau, G., additional, Pili, G., additional, Porcu, M., additional, Derudas, D., additional, Angelucci, E., additional, Ledda, A., additional, La Nasa, G., additional, Ossareh, S., additional, Asgari, M., additional, Savaj, S., additional, Ataipour, Y., additional, Abdi, E., additional, Malakoutian, T., additional, Rajaa, R., additional, Berkchi, F. Z., additional, Haffane, L., additional, Squalli, Z., additional, Rouass, L., additional, Al Hamany, Z., additional, Ezzaitouni, F., additional, Benamar, L., additional, Bayahya, R., additional, Ouzeddoun, N., additional, Gao-Yuan, H., additional, Yao, X., additional, Xin, C., additional, Zhen, C., additional, Yong-Chun, G., additional, Qing-Wen, W., additional, Hui-Ping, C., additional, Da-XI, J., additional, De-Hua, G., additional, Wei-Xin, H., additional, Zhi-Hong, L., additional, Fatima Zahra, B., additional, Laila, H., additional, Zoubair, S., additional, Naima, O., additional, Smykal-Jankowiak, K., additional, Niemir, Z., additional, Polcyn-Adamczak, M., additional, Szramka-Pawlak, B., additional, Zaba, R., additional, Zhang, C., additional, MA, Y., additional, Shen, P., additional, Ouyang, Y., additional, Pan, X., additional, Wang, Z., additional, Feng, X., additional, and Ni, L., additional
- Published
- 2012
- Full Text
- View/download PDF
16. Brain diffuse large B-cell lymphoma in a systemic lupus erythematosus patient treated with immunosuppressive agents including mycophenolate mofetil
- Author
-
Svobodova, B, primary, Hruskova, Z, additional, Rysava, R, additional, and Tesar, V, additional
- Published
- 2011
- Full Text
- View/download PDF
17. Evaluation of in vitro antioxidant activity of selected Peruvian medicinal plants
- Author
-
Svobodova, B, primary, Polesna, L, additional, Orsak, M, additional, Lachman, J, additional, Vadlejch, J, additional, and Kokoska, L, additional
- Published
- 2009
- Full Text
- View/download PDF
18. Antimicrobial activity of some medicinal barks used in Peruvian Amazon
- Author
-
Kloucek, P., Svobodova, B., Polesny, Z., Langrova, I., Smrcek, S., and Kokoska, L.
- Published
- 2007
- Full Text
- View/download PDF
19. Antimicrobial activity of some Yemeni medicinal plants
- Author
-
Taleb, M, primary, Svobodova, B, additional, Langrova, I, additional, and Kokoska, L, additional
- Published
- 2007
- Full Text
- View/download PDF
20. Antioxidant activity of selected Peruvian medicinal plants used in Calleria District
- Author
-
Svobodova, B, primary, Kokoska, L, additional, Kutilkova, L, additional, and Polesny, Z, additional
- Published
- 2007
- Full Text
- View/download PDF
21. Antibacterial screening of some Peruvian medicinal plants used in Callería District
- Author
-
Kloucek, P., primary, Polesny, Z., additional, Svobodova, B., additional, Vlkova, E., additional, and Kokoska, L., additional
- Published
- 2005
- Full Text
- View/download PDF
22. Treatment of Nephrological Patients with Rituximab-5 Years Experience
- Author
-
Hruskova, Z., Mareckova, H., Svobodova, B., Jancova, E., Bednarova, V., Romana Rysava, and Tesar, V.
23. Management of Information Support for Population Sheltering in the Czech Republic - the Case Study
- Author
-
Jakub Rak, Taraba, P., Svobodova, B., Safarik, Z., Tomek, M., Strohmandl, J., and Losek, V.
24. Transport of building material - Model for civil protection purposes
- Author
-
Rak, J., Vicar, D., Svobodova, B., Petr Svoboda, and Tomek, M.
25. Determination of Oxygen Radical Absorbance Capacity of Black Cumin (Nigella sativa) Seed Quinone Compounds
- Author
-
Tesarova, H., Svobodova, B., Kokoska, L., Petr Marsik, Pribylova, M., Landa, P., and Vadlejch, J.
26. Phenoxytacrine derivatives: Low-toxicity neuroprotectants exerting affinity to ifenprodil-binding site and cholinesterase inhibition.
- Author
-
Misiachna A, Svobodova B, Netolicky J, Chvojkova M, Kleteckova L, Prchal L, Novak M, Hrabinova M, Kucera T, Muckova L, Moravcova Z, Karasova JZ, Pejchal J, Blazek F, Malinak D, Hakenova K, Krausova BH, Kolcheva M, Ladislav M, Korabecny J, Pahnke J, Vales K, Horak M, and Soukup O
- Subjects
- Humans, Receptors, N-Methyl-D-Aspartate, Tacrine chemistry, Cholinesterase Inhibitors chemistry, Binding Sites, Cholinesterases, Acetylcholinesterase metabolism, Neuroprotective Agents pharmacology, Neuroprotective Agents therapeutic use, Chemical and Drug Induced Liver Injury, Alzheimer Disease drug therapy, Piperidines
- Abstract
Tacrine (THA), a long withdrawn drug, is still a popular scaffold used in medicinal chemistry, mainly for its good reactivity and multi-targeted effect. However, THA-associated hepatotoxicity is still an issue and must be considered in drug discovery based on the THA scaffold. Following our previously identified hit compound 7-phenoxytacrine (7-PhO-THA), we systematically explored the chemical space with 30 novel derivatives, with a focus on low hepatotoxicity, anticholinesterase action, and antagonism at the GluN1/GluN2B subtype of the NMDA receptor. Applying the down-selection process based on in vitro and in vivo pharmacokinetic data, two candidates, I-52 and II-52, selective GluN1/GluN2B inhibitors thanks to the interaction with the ifenprodil-binding site, have entered in vivo pharmacodynamic studies. Finally, compound I-52, showing only minor affinity to AChE, was identified as a lead candidate with favorable behavioral and neuroprotective effects using open-field and prepulse inhibition tests, along with scopolamine-based behavioral and NMDA-induced hippocampal lesion models. Our data show that compound I-52 exhibits low toxicity often associated with NMDA receptor ligands, and low hepatotoxicity, often related to THA-based compounds., Competing Interests: Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper., (Copyright © 2024 The Authors. Published by Elsevier Masson SAS.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
27. Tacrine First-Phase Biotransformation and Associated Hepatotoxicity: A Possible Way to Avoid Quinone Methide Formation.
- Author
-
Novak M, Vajrychova M, Koutsilieri S, Sismanoglou DC, Kobrlova T, Prchal L, Svobodova B, Korabecny J, Zarybnicky T, Raisova-Stuchlikova L, Skalova L, Lauschke VM, Kučera R, and Soukup O
- Subjects
- Humans, Animals, Mice, Rats, Tacrine toxicity, Biotransformation, Indolequinones, Chemical and Drug Induced Liver Injury, Methamphetamine
- Abstract
Tacrine was withdrawn from clinical use as a drug against Alzheimer's disease in 2013, mainly due to drug-induced liver injury. The culprit of tacrine-associated hepatotoxicity is believed to be the 7-OH-tacrine metabolite, a possible precursor of quinone methide (Q
meth ), which binds to intracellular -SH proteins. In our study, several different animal and human models (liver microsomes, primary hepatocytes, and liver slices) were used to investigate the biotransformation and hepatotoxicity of tacrine and its 7-substituted analogues (7-methoxy-, 7-phenoxy-, and 7-OH-tacrine). Our goal was to find the most appropriate in vitro model for studying tacrine hepatotoxicity and, through rational structure modifications, to develop derivatives of tacrine that are less prone to Qmeth formation. Our results show that none of animal models tested accurately mimic human tacrine biotransformation; however, the murine model seems to be more suitable than the rat model. Tacrine metabolism was overall most accurately mimicked in three-dimensional (3D) spheroid cultures of primary human hepatocytes (PHHs). In this system, tacrine and 7-methoxytacrine were hydroxylated to 7-OH-tacrine, whereas 7-phenoxytacrine formed, as expected, only trace amounts. Surprisingly, however, our study showed that 7-OH-tacrine was the least hepatotoxic (7-OH-tacrine < tacrine < 7-methoxytacrine < 7-phenoxytacrine) even after doses had been adjusted to achieve the same intracellular concentrations. The formation of Qmeth -cysteine and Qmeth -glutathione adducts after human liver microsome incubation was confirmed by all of the studied tacrine derivatives, but these findings were not confirmed after incubation with 3D PHH spheroids. Therefore, the presented data call into question the suggested previously hypothesized mechanism of toxicity, and the results open new avenues for chemical modifications to improve the safety of novel tacrine derivatives.- Published
- 2023
- Full Text
- View/download PDF
28. Structure-Guided Design of N -Methylpropargylamino-Quinazoline Derivatives as Multipotent Agents for the Treatment of Alzheimer's Disease.
- Author
-
Svobodova B, Pulkrabkova L, Panek D, Misiachna A, Kolcheva M, Andrys R, Handl J, Capek J, Nyvltova P, Rousar T, Prchal L, Hepnarova V, Hrabinova M, Muckova L, Tosnerova D, Karabanovich G, Finger V, Soukup O, Horak M, and Korabecny J
- Subjects
- Humans, Monoamine Oxidase Inhibitors therapeutic use, Cholinesterase Inhibitors therapeutic use, Monoamine Oxidase metabolism, Drug Design, Acetylcholinesterase metabolism, Structure-Activity Relationship, Alzheimer Disease drug therapy, Neuroblastoma drug therapy
- Abstract
Alzheimer's disease (AD) is a complex disease with an unknown etiology. Available treatments, limited to cholinesterase inhibitors and N -methyl-d-aspartate receptor (NMDAR) antagonists, provide symptomatic relief only. As single-target therapies have not proven effective, rational specific-targeted combination into a single molecule represents a more promising approach for treating AD, and is expected to yield greater benefits in alleviating symptoms and slowing disease progression. In the present study, we designed, synthesized, and biologically evaluated 24 novel N -methylpropargylamino-quinazoline derivatives. Initially, compounds were thoroughly inspected by in silico techniques determining their oral and CNS availabilities. We tested, in vitro, the compounds' effects on cholinesterases and monoamine oxidase A/B (MAO-A/B), as well as their impacts on NMDAR antagonism, dehydrogenase activity, and glutathione levels. In addition, we inspected selected compounds for their cytotoxicity on undifferentiated and differentiated neuroblastoma SH-SY5Y cells. We collectively highlighted II-6h as the best candidate endowed with a selective MAO-B inhibition profile, NMDAR antagonism, an acceptable cytotoxicity profile, and the potential to permeate through BBB. The structure-guided drug design strategy applied in this study imposed a novel concept for rational drug discovery and enhances our understanding on the development of novel therapeutic agents for treating AD.
- Published
- 2023
- Full Text
- View/download PDF
29. Neurotoxicity evoked by organophosphates and available countermeasures.
- Author
-
Pulkrabkova L, Svobodova B, Konecny J, Kobrlova T, Muckova L, Janousek J, Pejchal J, Korabecny J, and Soukup O
- Subjects
- Humans, Acetylcholinesterase metabolism, Reactive Oxygen Species, Organophosphates, Neuroinflammatory Diseases, Seizures, Cholinesterase Inhibitors toxicity, Neurotoxicity Syndromes etiology, Neurotoxicity Syndromes prevention & control, Organophosphate Poisoning drug therapy, Organophosphate Poisoning prevention & control
- Abstract
Organophosphorus compounds (OP) are a constant problem, both in the military and in the civilian field, not only in the form of acute poisoning but also for their long-lasting consequences. No antidote has been found that satisfactorily protects against the toxic effects of organophosphates. Likewise, there is no universal cure to avert damage after poisoning. The key mechanism of organophosphate toxicity is the inhibition of acetylcholinesterase. The overstimulation of nicotinic or muscarinic receptors by accumulated acetylcholine on a synaptic cleft leads to activation of the glutamatergic system and the development of seizures. Further consequences include generation of reactive oxygen species (ROS), neuroinflammation, and the formation of various other neuropathologists. In this review, we present neuroprotection strategies which can slow down the secondary nerve cell damage and alleviate neurological and neuropsychiatric disturbance. In our opinion, there is no unequivocal approach to ensure neuroprotection, however, sooner the neurotoxicity pathway is targeted, the better the results which can be expected. It seems crucial to target the key propagation pathways, i.e., to block cholinergic and, foremostly, glutamatergic cascades. Currently, the privileged approach oriented to stimulating GABA
A R by benzodiazepines is of limited efficacy, so that antagonizing the hyperactivity of the glutamatergic system could provide an even more efficacious approach for terminating OP-induced seizures and protecting the brain from permanent damage. Encouraging results have been reported for tezampanel, an antagonist of GluK1 kainate and AMPA receptors, especially in combination with caramiphen, an anticholinergic and anti-glutamatergic agent. On the other hand, targeting ROS by antioxidants cannot or already developed neuroinflammation does not seem to be very productive as other processes are also involved., (© 2022. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)- Published
- 2023
- Full Text
- View/download PDF
30. Rare genetic variability in human drug target genes modulates drug response and can guide precision medicine.
- Author
-
Zhou Y, Arribas GH, Turku A, Jürgenson T, Mkrtchian S, Krebs K, Wang Y, Svobodova B, Milani L, Schulte G, Korabecny J, Gastaldello S, and Lauschke VM
- Abstract
Interindividual variability in drug response constitutes a major concern in pharmacotherapy. While polymorphisms in genes involved in drug disposition have been extensively studied, drug target variability remains underappreciated. By mapping the genomic variability of all human drug target genes onto high-resolution crystal structures of drug target complexes, we identified 1094 variants localized within 6 Å of drug-binding pockets and directly affecting their geometry, topology, or physicochemical properties. We experimentally show that binding site variants affect pharmacodynamics with marked drug- and variant-specific differences. In addition, we demonstrate that a common BCHE variant confers resistance to tacrine and rivastigmine, which can be overcome by the use of derivatives based on squaric acid scaffolds or tryptophan conjugation. These findings underscore the importance of genetic drug target variability and demonstrate that integration of genomic data and structural information can inform personalized drug selection and genetically guided drug development to overcome resistance.
- Published
- 2021
- Full Text
- View/download PDF
31. Cellular pathology of the human heart in Duchenne muscular dystrophy (DMD): lessons learned from in vitro modeling.
- Author
-
Svobodova B, Jelinkova S, Pesl M, Beckerová D, Lacampagne A, Meli AC, and Rotrekl V
- Subjects
- Animals, Cardiomyopathy, Dilated pathology, Humans, Heart physiology, Muscular Dystrophy, Duchenne pathology
- Abstract
Duchenne muscular dystrophy is a genetic disorder where an X-linked mutation in the DMD gene initiates pathogenic development caused by the absence of dystrophin protein. This impacts primarily the evolution of a functional muscle tissue resulting in muscle weakness and later severe disability in young male patients leading to an early death. Patients in the final stage develop dilated cardiomyopathy leading ultimately to cardiac or respiratory failure as the cause of death. This review discusses recent advances in modeling the DMD pathology in vitro. It describes in detail the molecular abnormalities found on the cellular and organoid levels. The in vitro pathology is compared to that found in patients. Likewise, the drawbacks and limitations of current models are discussed.
- Published
- 2021
- Full Text
- View/download PDF
32. 7-phenoxytacrine is a dually acting drug with neuroprotective efficacy in vivo.
- Author
-
Kaniakova M, Korabecny J, Holubova K, Kleteckova L, Chvojkova M, Hakenova K, Prchal L, Novak M, Dolezal R, Hepnarova V, Svobodova B, Kucera T, Lichnerova K, Krausova B, Horak M, Vales K, and Soukup O
- Subjects
- Animals, HEK293 Cells, Hippocampus drug effects, Hippocampus metabolism, Humans, Male, Neuroprotective Agents chemistry, Rats, Rats, Wistar, Receptors, N-Methyl-D-Aspartate metabolism, Tacrine chemistry, Neuroprotective Agents pharmacology, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Tacrine pharmacology
- Abstract
N-methyl-D-aspartaterecepro receptor (NMDARs) are a subclass of glutamate receptors, which play an essential role in excitatory neurotransmission, but their excessive overactivation by glutamate leads to excitotoxicity. NMDARs are hence a valid pharmacological target for the treatment of neurodegenerative disorders; however, novel drugs targeting NMDARs are often associated with specific psychotic side effects and abuse potential. Motivated by currently available treatment against neurodegenerative diseases involving the inhibitors of acetylcholinesterase (AChE) and NMDARs, administered also in combination, we developed a dually-acting compound 7-phenoxytacrine (7-PhO-THA) and evaluated its neuropsychopharmacological and drug-like properties for potential therapeutic use. Indeed, we have confirmed the dual potency of 7-PhO-THA, i.e. potent and balanced inhibition of both AChE and NMDARs. We discovered that it selectively inhibits the GluN1/GluN2B subtype of NMDARs via an ifenprodil-binding site, in addition to its voltage-dependent inhibitory effect at both GluN1/GluN2A and GluN1/GluN2B subtypes of NMDARs. Furthermore, whereas NMDA-induced lesion of the dorsal hippocampus confirmed potent anti-excitotoxic and neuroprotective efficacy, behavioral observations showed also a cholinergic component manifesting mainly in decreased hyperlocomotion. From the point of view of behavioral side effects, 7-PhO-THA managed to avoid these, notably those analogous to symptoms of schizophrenia. Thus, CNS availability and the overall behavioral profile are promising for subsequent investigation of therapeutic use., (Copyright © 2021 Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
33. Cysteine-Targeted Insecticides against A. gambiae Acetylcholinesterase Are Neither Selective nor Reversible Inhibitors.
- Author
-
Gorecki L, Andrys R, Schmidt M, Kucera T, Psotka M, Svobodova B, Hrabcova V, Hepnarova V, Bzonek P, Jun D, Kuca K, Korabecny J, and Musilek K
- Abstract
Acetylcholinesterase cysteine-targeted insecticides against malaria vector Anopheles gambia and other mosquitos have already been introduced. We have applied the olefin metathesis for the preparation of cysteine-targeted insecticides in high yields. The prepared compounds with either a succinimide or maleimide moiety were evaluated on Anopheles gambiae and human acetylcholinesterase with relatively high irreversible inhibition of both enzymes but poor selectivity. The concept of cysteine binding was not proved by several methods, and poor stability was observed of the chosen most potent/selective compounds in a water/buffer environment. Thus, our findings do not support the proposed concept of cysteine-targeted selective insecticides for the prepared series of succinimide or maleimide compounds., Competing Interests: The authors declare no competing financial interest., (Copyright © 2019 American Chemical Society.)
- Published
- 2019
- Full Text
- View/download PDF
34. Nano-formulated curcumin (Lipodisq™) modulates the local inflammatory response, reduces glial scar and preserves the white matter after spinal cord injury in rats.
- Author
-
Krupa P, Svobodova B, Dubisova J, Kubinova S, Jendelova P, and Machova Urdzikova L
- Subjects
- Animals, Cicatrix metabolism, Cicatrix pathology, Drug Compounding, Inflammation Mediators metabolism, Male, Neuroglia drug effects, Neuroglia metabolism, Neuroglia pathology, Rats, Rats, Wistar, Spinal Cord Injuries metabolism, Spinal Cord Injuries pathology, White Matter metabolism, White Matter pathology, Cicatrix drug therapy, Curcumin administration & dosage, Inflammation Mediators antagonists & inhibitors, Nanoparticles administration & dosage, Spinal Cord Injuries drug therapy, White Matter drug effects
- Abstract
A highly water soluble, nano-formulated curcumin was used for the treatment of the experimental model of spinal cord injury (SCI) in rats. Nanocurcumin and a vehicle nanocarrier as a control, were delivered both locally, immediately after the spinal cord injury, and intraperitoneally during the 4 consecutive weeks after SCI. The efficacy of the treatment was assessed using behavioral tests, which were performed during the experiment, weekly for 9 weeks. The behavioral tests (BBB, flat beam test, rotarod, motoRater) revealed a significant improvement in the nanocurcumin treated group, compared to the nanocarrier control. An immunohistochemical analysis of the spinal cord tissue was performed at the end of the experiment and this proved a significant preservation of the white matter tissue, a reduced area of glial scaring and a higher amount of newly sprouted axons in the nanocurcumin treated group. The expression of endogenous genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, Nfkβ) and interleukins (IL-1β, TNF-α, IL-6, IL-12, CCL-5, IL-11, IL-10, IL-13) was evaluated by qPCR and showed changes in the expression of the inflammatory cytokines in the first two weeks after SCI., (Copyright © 2019 Elsevier Ltd. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
35. Exploring Structure-Activity Relationship in Tacrine-Squaramide Derivatives as Potent Cholinesterase Inhibitors.
- Author
-
Svobodova B, Mezeiova E, Hepnarova V, Hrabinova M, Muckova L, Kobrlova T, Jun D, Soukup O, Jimeno ML, Marco-Contelles J, and Korabecny J
- Subjects
- Cholinesterase Inhibitors chemical synthesis, Cholinesterase Inhibitors chemistry, Dose-Response Relationship, Drug, Humans, Kinetics, Models, Molecular, Molecular Structure, Quinine chemistry, Quinine pharmacology, Structure-Activity Relationship, Tacrine chemistry, Acetylcholinesterase metabolism, Butyrylcholinesterase metabolism, Cholinesterase Inhibitors pharmacology, Quinine analogs & derivatives, Tacrine pharmacology
- Abstract
Tacrine was the first drug to be approved for Alzheimer's disease (AD) treatment, acting as a cholinesterase inhibitor. The neuropathological hallmarks of AD are amyloid-rich senile plaques, neurofibrillary tangles, and neuronal degeneration. The portfolio of currently approved drugs for AD includes acetylcholinesterase inhibitors (AChEIs) and N -methyl-d-aspartate (NMDA) receptor antagonist. Squaric acid is a versatile structural scaffold capable to be easily transformed into amide-bearing compounds that feature both hydrogen bond donor and acceptor groups with the possibility to create multiple interactions with complementary sites. Considering the relatively simple synthesis approach and other interesting properties (rigidity, aromatic character, H-bond formation) of squaramide motif, we combined this scaffold with different tacrine-based derivatives. In this study, we developed 21 novel dimers amalgamating squaric acid with either tacrine, 6-chlorotacrine or 7-methoxytacrine representing various AChEIs. All new derivatives were evaluated for their anti-cholinesterase activities, cytotoxicity using HepG2 cell line and screened to predict their ability to cross the blood-brain barrier. In this contribution, we also report in silico studies of the most potent AChE and BChE inhibitors in the active site of these enzymes.
- Published
- 2019
- Full Text
- View/download PDF
36. The effect of 808 nm and 905 nm wavelength light on recovery after spinal cord injury.
- Author
-
Svobodova B, Kloudova A, Ruzicka J, Kajtmanova L, Navratil L, Sedlacek R, Suchy T, Jhanwar-Uniyal M, Jendelova P, and Machova Urdzikova L
- Subjects
- Animals, Antigens, CD genetics, Antigens, CD metabolism, Antigens, Differentiation, Myelomonocytic genetics, Antigens, Differentiation, Myelomonocytic metabolism, B7-2 Antigen genetics, B7-2 Antigen metabolism, Lectins, C-Type genetics, Lectins, C-Type metabolism, Locomotion, Male, Mannose Receptor, Mannose-Binding Lectins genetics, Mannose-Binding Lectins metabolism, Rats, Rats, Wistar, Receptors, Cell Surface genetics, Receptors, Cell Surface metabolism, Spinal Cord metabolism, Spinal Cord pathology, Spinal Cord Regeneration, Low-Level Light Therapy methods, Spinal Cord Injuries therapy
- Abstract
We investigated the effect of a Multiwave Locked System laser (with a simultaneous 808 nm continuous emission and 905 nm pulse emission) on the spinal cord after spinal cord injury (SCI) in rats. The functional recovery was measured by locomotor tests (BBB, Beam walking, MotoRater) and a sensitivity test (Plantar test). The locomotor tests showed a significant improvement of the locomotor functions of the rats after laser treatment from the first week following lesioning, compared to the controls. The laser treatment significantly diminished thermal hyperalgesia after SCI as measured by the Plantar test. The atrophy of the soleus muscle was reduced in the laser treated rats. The histopathological investigation showed a positive effect of the laser therapy on white and gray matter sparing. Our data suggests an upregulation of M2 macrophages in laser treated animals by the increasing number of double labeled CD68+/CD206+ cells in the cranial and central parts of the lesion, compared to the control animals. A shift in microglial/macrophage polarization was confirmed by gene expression analysis by significant mRNA downregulation of Cd86 (marker of inflammatory M1), and non-significant upregulation of Arg1 (marker of M2). These results demonstrated that the combination of 808 nm and 905 nm wavelength light is a promising non-invasive therapy for improving functional recovery and tissue sparing after SCI.
- Published
- 2019
- Full Text
- View/download PDF
37. A single point mutation in the TRPC3 lipid-recognition window generates supersensitivity to benzimidazole channel activators.
- Author
-
Svobodova B, Lichtenegger M, Platzer D, Di Giuro CML, de la Cruz GG, Glasnov T, Schreibmayer W, and Groschner K
- Subjects
- Calcium metabolism, Cells, Cultured, HEK293 Cells, Humans, Signal Transduction drug effects, Benzimidazoles pharmacology, Diglycerides genetics, Point Mutation genetics, TRPC Cation Channels genetics, TRPC Cation Channels metabolism
- Abstract
Mutation of a single residue within the recently identified lipid (diacylglycerol) recognition window of TRPC3 (G652A) was found to abolish channel activation via endogenous lipid mediators while retaining sensitivity to the non-lipid activator GSK1702934A (abb. GSK). The mechanism of this change in chemical sensing by TRPC3 was analysed by whole-cell and single channel electrophysiology as well as Ca
2+ imaging. Currents initiated by GSK or the structural (benzimidazole) analog BI-2 were significantly larger in cells expressing the G652A mutant as compared to wild type (WT) channels. Whole cell patch-clamp experiments revealed that enhanced sensitivity to benzimidazoles was not due to augmented potency but reflected enhanced efficacy of benzimidazoles. Single channel analysis demonstrated that neither unitary conductance nor I-V characteristics were altered by the G652A mutation, precluding altered pore architecture as the basis of enhanced efficacy. These experiments uncovered a distinct gating pattern of BI-2-activated G652A mutant channels, featuring a unique, long-lived open state. Moreover, G652A mutant channels lacked PLC/diacylglycerol mediated cross-desensitization for GSK activation as typically observed for TRPC3. Lack of desensitization in G652A channels enabled large GSK/BI-2-induced Ca2+ signals in conditions that fully desensitized TRPC3 WT channels. We demonstrate that the lipid-recognition window of TRPC3 determines both sensitivity to lipid mediators and chemical gating by benzimidazoles. TRPC3 mutations within this lipid interaction site are suggested as a basis for chemogenetic targeting of TRPC3-signaling., (Copyright © 2019 The Authors. Published by Elsevier Ltd.. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF
38. Principal component analysis of normalized full spectrum mass spectrometry data in multiMS-toolbox: An effective tool to identify important factors for classification of different metabolic patterns and bacterial strains.
- Author
-
Cejnar P, Kuckova S, Prochazka A, Karamonova L, and Svobodova B
- Subjects
- Bacteriological Techniques, Cronobacter sakazakii growth & development, Culture Media, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization methods, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization standards, Time Factors, Cronobacter sakazakii metabolism, Principal Component Analysis, Software, Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization statistics & numerical data
- Abstract
Rationale: Explorative statistical analysis of mass spectrometry data is still a time-consuming step. We analyzed critical factors for application of principal component analysis (PCA) in mass spectrometry and focused on two whole spectrum based normalization techniques and their application in the analysis of registered peak data and, in comparison, in full spectrum data analysis. We used this technique to identify different metabolic patterns in the bacterial culture of Cronobacter sakazakii, an important foodborne pathogen., Methods: Two software utilities, the ms-alone, a python-based utility for mass spectrometry data preprocessing and peak extraction, and the multiMS-toolbox, an R software tool for advanced peak registration and detailed explorative statistical analysis, were implemented. The bacterial culture of Cronobacter sakazakii was cultivated on Enterobacter sakazakii Isolation Agar, Blood Agar Base and Tryptone Soya Agar for 24 h and 48 h and applied by the smear method on an Autoflex speed MALDI-TOF mass spectrometer., Results: For three tested cultivation media only two different metabolic patterns of Cronobacter sakazakii were identified using PCA applied on data normalized by two different normalization techniques. Results from matched peak data and subsequent detailed full spectrum analysis identified only two different metabolic patterns - a cultivation on Enterobacter sakazakii Isolation Agar showed significant differences to the cultivation on the other two tested media. The metabolic patterns for all tested cultivation media also proved the dependence on cultivation time., Conclusions: Both whole spectrum based normalization techniques together with the full spectrum PCA allow identification of important discriminative factors in experiments with several variable condition factors avoiding any problems with improper identification of peaks or emphasis on bellow threshold peak data. The amounts of processed data remain still manageable. Both implemented software utilities are available free of charge from http://uprt.vscht.cz/ms., (Copyright © 2018 John Wiley & Sons, Ltd.)
- Published
- 2018
- Full Text
- View/download PDF
39. An optically controlled probe identifies lipid-gating fenestrations within the TRPC3 channel.
- Author
-
Lichtenegger M, Tiapko O, Svobodova B, Stockner T, Glasnov TN, Schreibmayer W, Platzer D, de la Cruz GG, Krenn S, Schober R, Shrestha N, Schindl R, Romanin C, and Groschner K
- Subjects
- Animals, Calcium chemistry, Glycine chemistry, HEK293 Cells, Humans, Kinetics, Light, Mutagenesis, Mutation, Optics and Photonics, Photochemistry, Protein Binding, Rats, Signal Transduction, TRPV Cation Channels chemistry, Ion Channel Gating, Lipids chemistry, TRPC Cation Channels chemistry
- Abstract
Transient receptor potential canonical (TRPC) channels TRPC3, TRPC6 and TRPC7 are able to sense the lipid messenger diacylglycerol (DAG). The DAG-sensing and lipid-gating processes in these ion channels are still unknown. To gain insights into the lipid-sensing principle, we generated a DAG photoswitch, OptoDArG, that enabled efficient control of TRPC3 by light. A structure-guided mutagenesis screen of the TRPC3 pore domain unveiled a single glycine residue behind the selectivity filter (G652) that is exposed to lipid through a subunit-joining fenestration. Exchange of G652 with larger residues altered the ability of TRPC3 to discriminate between different DAG molecules. Light-controlled activation-deactivation cycling of TRPC3 channels by an OptoDArG-mediated optical 'lipid clamp' identified pore domain fenestrations as pivotal elements of the channel´s lipid-sensing machinery. We provide evidence for a novel concept of lipid sensing by TRPC channels based on a lateral fenestration in the pore domain that accommodates lipid mediators to control gating.
- Published
- 2018
- Full Text
- View/download PDF
40. Does combined therapy of curcumin and epigallocatechin gallate have a synergistic neuroprotective effect against spinal cord injury?
- Author
-
Ruzicka J, Urdzikova LM, Svobodova B, Amin AG, Karova K, Dubisova J, Zaviskova K, Kubinova S, Schmidt M, Jhanwar-Uniyal M, and Jendelova P
- Abstract
Systematic inflammatory response after spinal cord injury (SCI) is one of the factors leading to lesion development and a profound degree of functional loss. Anti-inflammatory compounds, such as curcumin and epigallocatechin gallate (EGCG) are known for their neuroprotective effects. In this study, we investigated the effect of combined therapy of curcumin and EGCG in a rat model of acute SCI induced by balloon compression. Immediately after SCI, rats received curcumin, EGCG, curcumin + EGCG or saline [daily intraperitoneal doses (curcumin, 6 mg/kg; EGCG 17 mg/kg)] and weekly intramuscular doses (curcumin, 60 mg/kg; EGCG 17 mg/kg)] for 28 days. Rats were evaluated using behavioral tests (the Basso, Beattie, and Bresnahan (BBB) open-field locomotor test, flat beam test). Spinal cord tissue was analyzed using histological methods (Luxol Blue-cresyl violet staining) and immunohistochemistry (anti-glial fibrillary acidic protein, anti-growth associated protein 43). Cytokine levels (interleukin-1β, interleukin-4, interleukin-2, interleukin-6, macrophage inflammatory protein 1-alpha, and RANTES) were measured using Luminex assay. Quantitative polymerase chain reaction was performed to determine the relative expression of genes (Sort1, Fgf2, Irf5, Mrc1, Olig2, Casp3, Gap43, Gfap, Vegf, NfκB, Cntf) related to regenerative processes in injured spinal cord. We found that all treatments displayed significant behavioral recovery, with no obvious synergistic effect after combined therapy of curcumin and ECGC. Curcumin and EGCG alone or in combination increased axonal sprouting, decreased glial scar formation, and altered the levels of macrophage inflammatory protein 1-alpha, interleukin-1β, interleukin-4 and interleukin-6 cytokines. These results imply that although the expected synergistic response of this combined therapy was less obvious, aspects of tissue regeneration and immune responses in severe SCI were evident., Competing Interests: The authors declare that the study was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
- Published
- 2018
- Full Text
- View/download PDF
41. A green tea polyphenol epigallocatechin-3-gallate enhances neuroregeneration after spinal cord injury by altering levels of inflammatory cytokines.
- Author
-
Machova Urdzikova L, Ruzicka J, Karova K, Kloudova A, Svobodova B, Amin A, Dubisova J, Schmidt M, Kubinova S, Jhanwar-Uniyal M, and Jendelova P
- Subjects
- Animals, Axons drug effects, Behavior, Animal drug effects, Catechin administration & dosage, Inflammation Mediators metabolism, Male, Myelitis complications, NF-kappa B metabolism, Rats, Wistar, Signal Transduction drug effects, Spinal Cord Injuries complications, Spinal Cord Injuries pathology, Spinal Cord Injuries prevention & control, Tea chemistry, Catechin analogs & derivatives, Cytokines metabolism, Myelitis metabolism, Nerve Regeneration drug effects, Neuroprotective Agents administration & dosage, Spinal Cord Injuries metabolism
- Abstract
Spinal cord injury (SCI) is a debilitating condition which is characterized by an extended secondary injury due to the presence of inflammatory local milieu. Epigallocatechin gallate (EGCG) appears to possess strong neuroprotective properties. Here, we evaluated the beneficial effect of EGCG on recovery from SCI. Male Wistar rats were given either EGCG or saline directly to the injured spinal cord and thereafter a daily IP injection. Behavior recovery was monitored by BBB, plantar, rotarod and flat-beam tests. The levels of inflammatory cytokines were determined on days 1, 3, 7, 10 and 14 after SCI. Additionally, NF-κB pathway activity was evaluated. The results demonstrated that EGCG-treated rats displayed a superior behavioral performance in a flat beam test, higher axonal sprouting and positive remodelation of glial scar. Cytokine analysis revealed a reduction in IL-6, IL2, MIP1α and RANTES levels on days 1 and 3, and an upregulation of IL-4, IL-12p70 and TNFα 1 day following SCI in EGCG-treated rats. Treatment with EGCG was effective in decreasing the nuclear translocation of subunit p65 (RelA) of the NF-κB dimer, and therefore canonical NF-κB pathway attenuation. A significant increase in the gene expression of growth factors (FGF2 and VEGF), was noted in the spinal cord of EGCG-treated rats. Further, EGCG influenced expression of M1 and M2 macrophage markers. Our results have demonstrated a therapeutic value of EGCG in SCI, as observed by better behavioral performance measured by flat beam test, modulation of inflammatory cytokines and induction of higher axonal sprouting., (Copyright © 2017 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
42. Non-edible parts of Solanum stramoniifolium Jacq. - a new potent source of bioactive extracts rich in phenolic compounds for functional foods.
- Author
-
Svobodova B, Barros L, Sopik T, Calhelha RC, Heleno S, Alves MJ, Walcott S, Kuban V, and Ferreira ICFR
- Subjects
- Animals, Anti-Bacterial Agents chemistry, Anti-Bacterial Agents isolation & purification, Anti-Bacterial Agents pharmacology, Anti-Inflammatory Agents immunology, Anti-Inflammatory Agents isolation & purification, Anti-Inflammatory Agents pharmacology, Bacteria drug effects, Macrophages drug effects, Macrophages immunology, Mice, Nitric Oxide immunology, Phenols isolation & purification, Plant Extracts isolation & purification, Plant Leaves chemistry, Plant Roots chemistry, Plant Stems chemistry, RAW 264.7 Cells, Functional Food analysis, Phenols chemistry, Phenols pharmacology, Plant Extracts chemistry, Plant Extracts pharmacology, Solanum chemistry
- Abstract
Extracts prepared from leaves, roots, and stems of Solanum stramoniifolium Jacq. (Solanaceae) in 80% ethanol have been tested for their in vitro antioxidant, anti-inflammatory, antimicrobial, and cytotoxic activities with an aim to find new sources of substances for functional foods and food additives. The root extract revealed the highest antioxidant activity in all assays exceeding the trolox capacity, and was the only extract that inhibited nitric oxide production in mouse macrophage cells, showing also the capacity to suppress the growth of all tested human tumor cell lines (MCF-7, NCI-H460, HeLa and HepG2). The leaf extract showed the strongest antimicrobial activity inhibiting all tested clinical isolates. To the author's best knowledge it was the first time that all individual parts of this plant were tested for biological activity together with the phenolic compound characterization.
- Published
- 2017
- Full Text
- View/download PDF
43. Intensified Microwave-Assisted N-Acylation Procedure - Synthesis and Activity Evaluation of TRPC3 Channel Agonists with a 1,3-Dihydro-2 H -benzo[ d ]imidazol-2-one Core.
- Author
-
de la Cruz GG, Svobodova B, Lichtenegger M, Tiapko O, Groschner K, and Glasnov T
- Abstract
Upon controlled microwave heating and using cyanuric chloride as a coupling reagent, an efficient amidation procedure for the synthesis of 1,3-dihydro-2 H -benzo[ d ]imidazol-2-one-based agonists of TRPC3/6 ion channels has been developed. Compared to the few conventional protocols, a drastic reduction in processing time from ca. 2 days down to 10 minutes was achieved accompanied by significantly improved product yields. The robustness of the method was confirmed by 18 additional examples including aromatic, aliphatic, and heterocyclic amines and acids. The obtained agonists were screened for biological activity at 1 μM concentration and few structure-activity relations have been established.
- Published
- 2017
- Full Text
- View/download PDF
44. Reprint of "Mechanisms of lipid regulation and lipid gating in TRPC channels".
- Author
-
Svobodova B and Groschner K
- Subjects
- Animals, Humans, Models, Biological, Oxidation-Reduction, Signal Transduction, Ion Channel Gating, Lipid Metabolism, TRPC Cation Channels metabolism
- Abstract
TRPC proteins form cation channels that integrate and relay cellular signals by mechanisms involving lipid recognition and lipid-dependent gating. The lipohilic/amphiphilic molecules that function as cellular activators or modulators of TRPC proteins span a wide range of chemical structures. In this context, cellular redox balance is likely linked to the lipid recognition/gating features of TRPC channels. Both classical ligand-protein interactions as well as indirect and promiscuous sensory mechanisms have been proposed. Some of the recognition processes are suggested to involve ancillary lipid-binding scaffolds or regulators as well as dynamic protein-protein interactions determined by bilayer architecture. A complex interplay of protein-protein and protein-lipid interactions is likely to govern the gating and/or plasma membrane recruitment of TRPC channels, thereby providing a distinguished platform for signal integration and coincident signal detection. Both the primary molecular event(s) of lipid recognition by TRPC channels as well as the transformation of these events into distinct gating movements is poorly understood at the molecular level, and it remains elusive whether lipid sensing in TRPCs is conferred to a distinct sensor domain. Recent structural information on the molecular action of lipophilic activators in distantly related members of the TRP superfamily encourages speculations on TRPC gating mechanisms involved in lipid recognition/gating. This review aims to provide an update on the current understanding of the lipid-dependent control of TRPC channels with focus on the TRPC lipid sensing, signal-integration hub and a short discussion of potential links to redox signaling., (Copyright © 2016. Published by Elsevier Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
45. Mechanisms of lipid regulation and lipid gating in TRPC channels.
- Author
-
Svobodova B and Groschner K
- Subjects
- Animals, Humans, Models, Biological, Oxidation-Reduction, TRPC Cation Channels chemistry, Lipid Metabolism, TRPC Cation Channels metabolism
- Abstract
TRPC proteins form cation channels that integrate and relay cellular signals by mechanisms involving lipid recognition and lipid-dependent gating. The lipohilic/amphiphilic molecules that function as cellular activators or modulators of TRPC proteins span a wide range of chemical structures. In this context, cellular redox balance is likely linked to the lipid recognition/gating features of TRPC channels. Both classical ligand-protein interactions as well as indirect and promiscuous sensory mechanisms have been proposed. Some of the recognition processes are suggested to involve ancillary lipid-binding scaffolds or regulators as well as dynamic protein-protein interactions determined by bilayer architecture. A complex interplay of protein-protein and protein-lipid interactions is likely to govern the gating and/or plasma membrane recruitment of TRPC channels, thereby providing a distinguished platform for signal integration and coincident signal detection. Both the primary molecular event(s) of lipid recognition by TRPC channels as well as the transformation of these events into distinct gating movements is poorly understood at the molecular level, and it remains elusive whether lipid sensing in TRPCs is conferred to a distinct sensor domain. Recent structural information on the molecular action of lipophilic activators in distantly related members of the TRP superfamily encourages speculations on TRPC gating mechanisms involved in lipid recognition/gating. This review aims to provide an update on the current understanding of the lipid-dependent control of TRPC channels with focus on the TRPC lipid sensing, signal-integration hub and a short discussion of potential links to redox signaling., (Copyright © 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2016
- Full Text
- View/download PDF
46. Training of different endoscopic skills on ex-vivo animal model.
- Author
-
Martinek J, Stefanova M, Suchanek S, Zavada F, Svobodova B, Strosova A, and Zavoral M
- Subjects
- Adult, Animals, Clinical Competence, Computer Simulation, Female, Humans, Male, Middle Aged, Models, Animal, User-Computer Interface, Education, Medical, Graduate methods, Endoscopy education, Gastroenterology education
- Abstract
Introduction: Virtual reality simulator and ex vivo animal models are used for training of both basic and advanced endoscopic techniques. The aim of this study was to assess whether hands-on training on ex vivo animal model improves endoscopic skills. Four different endoscopic techniques were practiced: endoscopic resection, endoscopic stenting, application of the over-the-scope (OVESCO) clip, and endoscopic submucosal dissection (ESD)., Methods: Except for 2 participants, all trainees participated in a 1-day course. Two remaining participants took part in 7 ESD courses. All training courses consisted of theoretical introduction and a 6-hour training on Erlangen Active Training Simulator. The endoscopic skills were assessed before and after the training session by 2 independent assessors. Each assessor evaluated the skills by using a score on a scale of 1 to 5, where 1 stands for excellent and 5 for insufficient. Each assessor also assessed whether the procedure was successfully completed. The main outcome measurement was the percentage of participants who successfully completed the procedure during the test., Results: For endoscopic resection, endoscopists (n = 15) improved their skills (median [10th and 90th percentiles] score before training, 3.5 [2.7-4.2]; after training 1.5 [1-2.3], P < 0.001). Seven procedures were assessed as successful before the course (47%); after the training, 13 procedures were assessed as successful (87%) (P = 0.02). For stenting, participants (n = 15) significantly improved their abilities to place both self-expandible metallic and plastic stents. For OVESCO clip (n = 10), participants (n = 10) improved their skills to prepare and apply the clip (given the score of 4.5 [3.9-5] before and 2.0 [1.2-2.8] after, P < 0.01). Before the training, only 1 clip application had been successful (10%), whereas the number rose to 9 after the course (90%). For endoscopic submucosal dissection (n = 10), eight participants of the 1-day course did not improve their competences (with scores of 4.2 [3.8-5] before and 4.0 [3.1-4.8] after, nonsignificant). Two participants who had undertaken 7 ESD courses improved their skills (with scores of 4 before and 1.6 after); given the small number of participants, this finding is statistically insignificant., Limitation: The effect of training on clinical outcome was not investigated. There was a lack of pretraining versus posttraining tests blinding., Conclusions: A 1-day training course on ex vivo animal model improves general endoscopic competence on simulator in endoscopic resection, insertion of stents, and application of OVESCO clips. In contrast, 1-day course does not improve skills for ESD that requires a higher number of training courses.
- Published
- 2014
- Full Text
- View/download PDF
47. Kidney biopsy is a sensitive tool for retrospective diagnosis of PLA2R-related membranous nephropathy.
- Author
-
Svobodova B, Honsova E, Ronco P, Tesar V, and Debiec H
- Subjects
- Adult, Aged, Biopsy, Feasibility Studies, Female, Follow-Up Studies, Glomerular Filtration Rate, Glomerulonephritis, Membranous blood, Humans, Kidney Function Tests, Male, Middle Aged, Prognosis, Retrospective Studies, Risk Factors, Young Adult, Antibodies, Anti-Idiotypic blood, Biomarkers blood, Glomerulonephritis, Membranous diagnosis, Receptors, Phospholipase A2 immunology
- Abstract
Background: Antibodies against M-type phospholipase A2 receptor (PLA2R) are serological markers of disease activity in patients with idiopathic membranous nephropathy (iMN). To determine the most sensitive test for the diagnosis of PLA2R-related membranous nephropathy (MN) irrespective of sampling time, we investigated the presence of PLA2R in glomerular immune deposits and assessed circulating anti-PLA2R antibodies in a retrospective cohort of Czech patients with idiopathic, lupus and other few secondary MN., Methods: We tested archival paraffin-embedded kidney biopsies of 84 consecutive patients with biopsy-proven MN, for the presence of PLA2R in glomerular immune deposits and we measured circulating anti-PLA2R antibodies using the indirect immunofluorescence test, all reagents being commercially available., Results: In 45 of 65 (69%) patients with iMN, PLA2R was detected in a finely granular pattern in sub-epithelial deposits along glomerular capillary loops. Circulating anti-PLA2R antibodies were detected in 20 of 31 (65%) sera from patients sampled during active disease. Six patients with active disease were negative for circulating anti-PLA2R antibodies despite PLA2R antigen positivity in the kidney biopsies. Only 8 of 37 (22%) sera sampled at the time of remission were PLA2R positive while PLA2R antigen was found in 22 of the 37 (59%) corresponding biopsies. PLA2R was found in immune deposits in 3 patients with secondary MN (2 with hepatitis B, and 1 with sarcoidosis) but in none of the 16 patients with lupus., Conclusions: In case of delayed serum sampling, assessment of PLA2R antigen in biopsy specimens is more sensitive than the serological test for the diagnosis of PLA2R-related MN which can be established retrospectively.
- Published
- 2013
- Full Text
- View/download PDF
48. Determination of oxygen radical absorbance capacity of black cumin (Nigella sativa) seed quinone compounds.
- Author
-
Tesarova H, Svobodova B, Kokoska L, Marsik P, Pribylova M, Landa P, and Vadlejch J
- Subjects
- Benzoquinones pharmacology, Free Radical Scavengers pharmacology, Seeds chemistry, Thymol analogs & derivatives, Thymol pharmacology, Antioxidants pharmacology, Nigella sativa chemistry, Quinones pharmacology
- Abstract
In this study, the antioxidant capacities of main quinone constituents of Nigella sativa seeds, namely dithymoquinone (1), thymohydroquinone (2) and thymoquinone (3), were compared using DPPH and ORAC methods. The best scavenging activity was produced by 2, which showed a remarkable activity of 2.60 Trolox equivalents (TE) in a concentration range between 1.6 and 6.4 microg/mL and IC50 value of 2.4 microg/mL in ORAC and DPPH assays, respectively. Contrastingly, 3 possessed only weak DPPH scavenging efficacy (IC50 = 170 microg/mL) but significant antioxidative action of 1.91 TE in ORAC assay. No effect has been observed for 1. Additionally, modified protocol for synthesis of 2 has been developed with aim to enhance its availability for further studies as well as for its future potential use. Based on the results of this study, we conclude that 2 could be considered as a compound with prospective antioxidative properties.
- Published
- 2011
49. In vitro antifungal effect of black cumin seed quinones against dairy spoilage yeasts at different acidity levels.
- Author
-
Halamova K, Kokoska L, Flesar J, Sklenickova O, Svobodova B, and Marsik P
- Subjects
- Animals, Colony Count, Microbial, Consumer Product Safety, Dose-Response Relationship, Drug, Food Preservatives pharmacology, Humans, Hydrogen-Ion Concentration, Yeasts growth & development, Antifungal Agents pharmacology, Food Preservation methods, Milk microbiology, Nigella sativa chemistry, Quinones pharmacology, Yeasts drug effects
- Abstract
The antiyeast activity of the black cumin seed (Nigella sativa) quinones dithymoquinone, thymohydroquinone (THQ), and thymoquinone (TQ) were evaluated in vitro with a broth microdilution method against six dairy spoilage yeast species. Antifungal effects of the quinones were compared with those of preservatives commonly used in milk products (calcium propionate, natamycin, and potassium sorbate) at two pH levels (4.0 and 5.5). THQ and TQ possessed significant antiyeast activity and affected the growth of all strains tested at both pH levels, with MICs ranging from 8 to 128 μg/ml. With the exception of the antibiotic natamycin, the inhibitory effects of all food preservatives against the yeast strains tested in this study were strongly affected by differences in pH, with MICs of ≥16 and ≥512 μg/ml at pH 4.0 and 5.5, respectively. These findings suggest that HQ and TQ are effective antiyeast agents that could be used in the dairy industry as chemical preservatives of natural origin.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.